Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization.
Journal: ImmunoHorizons
Published: December 17, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers.
Journal: Cancer discovery
Published: June 24, 2024
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.
Journal: Annals of hematology
Published: March 27, 2024
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager.
Journal: Clinical pharmacology and therapeutics
Published: March 19, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Journal: Targeted oncology
Published: March 10, 2024
Immunosuppressive therapy in severe aplastic anemia.
Journal: Seminars in hematology
Published: December 23, 2021
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 06, 2021
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Journal: British journal of clinical pharmacology
Published: April 01, 2021
Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
Journal: British journal of haematology
Published: June 29, 2020
Last Updated: 09/26/2026